Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen

Korean Multiple Myeloma Working Party (KMMWP)

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Although the introduction of novel agents improved the survival outcomes in patients with multiple myeloma (MM), some patients died within one year (early mortality, EM) following diagnosis. In this study, we evaluated the EM rate, and investigated the risk factors associated with EM in MM patients. Methods: Retrospective data from 542 patients who were initially treated with a novel agent-containing regimen were analyzed. Results: The median overall survival (OS) for the entire cohort was 56.5 months. The median OS in the 2010-2014 group was longer than in the 2002-2009 group (59.2 months vs. 49.1 months, P = 0.054). The rate of EM was 13.8 %, and the most common causes of EM were infection and comorbidity. In multivariate analysis, the age-adjusted Charlson comorbidity index (ACCI ≥ 4), low body mass index (BMI < 20 kg/m 2 ), thrombocytopenia, and renal failure were significantly associated with EM. The presence of none, 1, or ≥ 2 factors was associated with a 4.1 %, 14.3 %, or 27.4 % risk of EM (P < 0.001), respectively. The median OS times were significantly different depending on the presence of factors associated with EM (P < 0.001). Conclusions: In conclusion, the ACCI (≥ 4), low BMI, thrombocytopenia and renal failure were strong predictors for EM in the novel agent era. The results of this study will help to identify patients at high risk for EM, and may be helpful to more accurately predict prognosis of MM patients in the novel-agent era.

Original languageEnglish
Article number613
JournalBMC cancer
Volume16
Issue number1
DOIs
Publication statusPublished - 2016 Aug 8

Fingerprint

Multiple Myeloma
Mortality
Survival
Renal Insufficiency
Comorbidity
Thrombocytopenia
Body Mass Index
Multivariate Analysis
Infection

All Science Journal Classification (ASJC) codes

  • Oncology
  • Genetics
  • Cancer Research

Cite this

@article{2840f97001364af999375817de07d801,
title = "Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen",
abstract = "Background: Although the introduction of novel agents improved the survival outcomes in patients with multiple myeloma (MM), some patients died within one year (early mortality, EM) following diagnosis. In this study, we evaluated the EM rate, and investigated the risk factors associated with EM in MM patients. Methods: Retrospective data from 542 patients who were initially treated with a novel agent-containing regimen were analyzed. Results: The median overall survival (OS) for the entire cohort was 56.5 months. The median OS in the 2010-2014 group was longer than in the 2002-2009 group (59.2 months vs. 49.1 months, P = 0.054). The rate of EM was 13.8 {\%}, and the most common causes of EM were infection and comorbidity. In multivariate analysis, the age-adjusted Charlson comorbidity index (ACCI ≥ 4), low body mass index (BMI < 20 kg/m 2 ), thrombocytopenia, and renal failure were significantly associated with EM. The presence of none, 1, or ≥ 2 factors was associated with a 4.1 {\%}, 14.3 {\%}, or 27.4 {\%} risk of EM (P < 0.001), respectively. The median OS times were significantly different depending on the presence of factors associated with EM (P < 0.001). Conclusions: In conclusion, the ACCI (≥ 4), low BMI, thrombocytopenia and renal failure were strong predictors for EM in the novel agent era. The results of this study will help to identify patients at high risk for EM, and may be helpful to more accurately predict prognosis of MM patients in the novel-agent era.",
author = "{Korean Multiple Myeloma Working Party (KMMWP)} and Jung, {Sung Hoon} and Cho, {Min Seok} and Kim, {Hee Kyung} and Kim, {Seok Jin} and Kihyun Kim and Cheong, {June Won} and Kim, {Soo Jeoong} and Jinseok Kim and Ahn, {Jae Sook} and Kim, {Yeo Kyeoung} and Yang, {Deok Hwan} and Kim, {Hyeoung Joon} and Lee, {Je Jung}",
year = "2016",
month = "8",
day = "8",
doi = "10.1186/s12885-016-2645-y",
language = "English",
volume = "16",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. / Korean Multiple Myeloma Working Party (KMMWP).

In: BMC cancer, Vol. 16, No. 1, 613, 08.08.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen

AU - Korean Multiple Myeloma Working Party (KMMWP)

AU - Jung, Sung Hoon

AU - Cho, Min Seok

AU - Kim, Hee Kyung

AU - Kim, Seok Jin

AU - Kim, Kihyun

AU - Cheong, June Won

AU - Kim, Soo Jeoong

AU - Kim, Jinseok

AU - Ahn, Jae Sook

AU - Kim, Yeo Kyeoung

AU - Yang, Deok Hwan

AU - Kim, Hyeoung Joon

AU - Lee, Je Jung

PY - 2016/8/8

Y1 - 2016/8/8

N2 - Background: Although the introduction of novel agents improved the survival outcomes in patients with multiple myeloma (MM), some patients died within one year (early mortality, EM) following diagnosis. In this study, we evaluated the EM rate, and investigated the risk factors associated with EM in MM patients. Methods: Retrospective data from 542 patients who were initially treated with a novel agent-containing regimen were analyzed. Results: The median overall survival (OS) for the entire cohort was 56.5 months. The median OS in the 2010-2014 group was longer than in the 2002-2009 group (59.2 months vs. 49.1 months, P = 0.054). The rate of EM was 13.8 %, and the most common causes of EM were infection and comorbidity. In multivariate analysis, the age-adjusted Charlson comorbidity index (ACCI ≥ 4), low body mass index (BMI < 20 kg/m 2 ), thrombocytopenia, and renal failure were significantly associated with EM. The presence of none, 1, or ≥ 2 factors was associated with a 4.1 %, 14.3 %, or 27.4 % risk of EM (P < 0.001), respectively. The median OS times were significantly different depending on the presence of factors associated with EM (P < 0.001). Conclusions: In conclusion, the ACCI (≥ 4), low BMI, thrombocytopenia and renal failure were strong predictors for EM in the novel agent era. The results of this study will help to identify patients at high risk for EM, and may be helpful to more accurately predict prognosis of MM patients in the novel-agent era.

AB - Background: Although the introduction of novel agents improved the survival outcomes in patients with multiple myeloma (MM), some patients died within one year (early mortality, EM) following diagnosis. In this study, we evaluated the EM rate, and investigated the risk factors associated with EM in MM patients. Methods: Retrospective data from 542 patients who were initially treated with a novel agent-containing regimen were analyzed. Results: The median overall survival (OS) for the entire cohort was 56.5 months. The median OS in the 2010-2014 group was longer than in the 2002-2009 group (59.2 months vs. 49.1 months, P = 0.054). The rate of EM was 13.8 %, and the most common causes of EM were infection and comorbidity. In multivariate analysis, the age-adjusted Charlson comorbidity index (ACCI ≥ 4), low body mass index (BMI < 20 kg/m 2 ), thrombocytopenia, and renal failure were significantly associated with EM. The presence of none, 1, or ≥ 2 factors was associated with a 4.1 %, 14.3 %, or 27.4 % risk of EM (P < 0.001), respectively. The median OS times were significantly different depending on the presence of factors associated with EM (P < 0.001). Conclusions: In conclusion, the ACCI (≥ 4), low BMI, thrombocytopenia and renal failure were strong predictors for EM in the novel agent era. The results of this study will help to identify patients at high risk for EM, and may be helpful to more accurately predict prognosis of MM patients in the novel-agent era.

UR - http://www.scopus.com/inward/record.url?scp=84981268256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981268256&partnerID=8YFLogxK

U2 - 10.1186/s12885-016-2645-y

DO - 10.1186/s12885-016-2645-y

M3 - Article

C2 - 27501959

AN - SCOPUS:84981268256

VL - 16

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 613

ER -